Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.

Journal of the American College of Surgeons - 1 Apr 2015

Johnson Adam S, Crandall Holly, Dahlman Kimberly, Kelley Mark C

Abstract excerpt

BACKGROUND: We conducted a prospective trial of BRAF and mitogen-activated protein kinase kinase (MEK) targeted therapy in advanced, operable BRAF mutation-positive melanoma to determine feasibility, tumor response rates, and biomarkers of response and resistance. STUDY DESIGN: Thirteen patients with locally or regionally advanced BRAF mutation-positive melanoma received dabrafenib 150 mg po bid for 14 days,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Feasibility Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Kinase 1

Share to Oximes

Share to Preoperative Care

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 25797743
DOI: 10.1016/j.jamcollsurg.2014.12.057

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.PMID 25797743Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

Targeted Therapy for Melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.